In our study, the high correlation between CSNK1A1 and NFATC3 is associated with poor survival in the ER-negative group, which suggests that pharmacological inhibition of NFATC3 by targeting CSNK1A1 could be of therapeutic interest for breast cancer patients. Here, CSNK1A1 is linked to breast carcinoma.